Let's Talk: Contrast Enhanced Mammography with Stereotactic Biopsy

Ryan Gabriel, MD
Director of Breast Imaging
Henrico Doctors’ Hospital 
Richmond, VA 

In this CME presentation, Dr. Gabriel will share his experience with contrast enhanced stereotactic biopsy as a novel method to biopsy enhancing lesions seen on contrast enhanced mammography. He will describe the procedure of contrast enhanced stereotactic biopsy, including similarities and differences with traditional stereotactic biopsy. He will also demonstrate how contrast enhanced stereotactic biopsy can be used as an alternative to MRI guided biopsy.

Upon completion of this lecture, participants will be able to:

  • Understand how CEM can be used in clinical practice
  • Review biopsy techniques for sampling CEM identified lesions
  • Introduce the concept of CEM Biopsy
  • Review how CEM biopsy is performed including limitations

Release Date: 1/13/2023
Expiration Date: 1/12/2026


Ryan Gabriel, MD
Consultant: Hologic, Inc.

All of the relevant financial relationships for this faculty have been mitigated by peer review completed by peers with no relevant financial relationships to disclose. 

None of the other program directors/planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 



World Class CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

World Class CME designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Society of Radiologic Technologists Credit has approved this activity as follows:

Reference No. Cat. Activity Title Start Date Expires Credit
NCZ02330016 A Let's Talk Contrast Enhanced Mammography with Stereotactic Biopsy 2/15/2023 3/1/2026 1


This activity may be available in multiple formats or from different sponsors. A self-learning activity can be completed only once per biennium


World Class CME relies on its CME faculty to provide program content that is evidence-based and free of commercial bias. Therefore, in accordance with ACCME standards, any faculty, program director, reviewer and/or provider industry relationships will be disclosed and resolved. Speakers are required to openly disclose any limitations of data or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations.

This activity is supported by an unrestricted educational grant from Hologic, Inc.

Instructions to Receive Credit:  After viewing the video, click on the “Take the Quiz” button and complete the post-activity quiz.  After completing the quiz, fill out the evaluation form and submit.  Your CME certificate will then be emailed to you


1Dromain C., Thibault, F., Muller, S. et al. Dual-energy contrast-enhanced digital mammography: initial clinical results. Eur Radiol (2011) 21(3):565-574

2 Jochelson et al. Radiology 266 (3) (2013) 743–751

Sudhir, R., Sannapareddy, K., Potlapalli, A., Krishnamurthy, P. B., Buddha, S., & Koppula, V. (2021). Diagnostic accuracy of contrast-enhanced digital mammography in breast cancer detection in comparison to tomosynthesis, synthetic 2D mammography and tomosynthesis combined with ultrasound in women with dense breast. The British Journal of Radiology94(1118). 

1. Jules H. Sumkin, Wendie A. Berg, Gloria J. Carter, Andriy I. Bandos, Denise M. Chough, Marie A. Ganott, Christiane M. Hakim, Amy E. Kelly, Margarita L. ZuleyGolbahar Houshmand, Maria I. Anello, and David Gur. Diagnostic Performance of MRI, Molecular Breast Imaging, and Contrast-enhanced Mammography in Women with Newly Diagnosed Breast Cancer​ Radiology 2019 293:3, 531-540 

2. Patel, B.K., Hilal, T., Covington, M. et al. Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy. Ann Surg Oncol 25, 1350–1356 (2018).

Take The Survey and Quiz